DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Comparison of isepamicin with amikacin for the empirical treatment of febrile neutropenic children with malignancies.

Author(s): Maltezou HC, Baka M, Gombakis N, Koliouskas DE, Kosmidou H, Malaka-Zafiriou E, Kafetzis DA

Affiliation(s): University of Athens Second Department of Pediatrics, P. and A. Kyriakou Children's Hospital, Athens, 11527 Greece.

Publication date & source: 2001-10, Int J Antimicrob Agents., 18(4):383-6.

Publication type: Clinical Trial; Comparative Study ; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

The efficacy and safety of isepamicin at 7.5 mg/kg i.v. q 12 h was prospectively compared with that of amikacin at the same dose for the treatment of febrile neutropenic children with malignancies. Thirty-nine patients were enrolled in the study; 25 received isepamicin and 14 amikacin. Clinical and bacteriological response rates were 100% for both groups. No adverse events occurred. Median peak serum levels were 19.7 mg/l for isepamicin and 19.20 mg/l for amikacin. Median trough serum levels were 0.72 mg/l for isepamicin and 0.68 mg/l for amikacin. It was concluded that isepamicin was as effective and safe as amikacin for the treatment of febrile neutropenic children with malignancies, and might be used in areas where resistance to other aminoglycosides is a problem.

Page last updated: 2007-02-12

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017